Insider Selling: Nkarta, Inc. (NASDAQ:NKTX) CEO Sells 17,378 Shares of Stock

Nkarta, Inc. (NASDAQ:NKTX) CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the transaction, the chief executive officer now directly owns 319,859 shares in the company, valued at $703,689.80. This trade represents a 5.15 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Nkarta Stock Performance

Shares of NASDAQ:NKTX opened at $2.47 on Friday. Nkarta, Inc. has a 52 week low of $2.08 and a 52 week high of $16.24. The company’s fifty day moving average is $2.52 and its 200-day moving average is $4.18. The company has a market capitalization of $174.31 million, a PE ratio of -1.31 and a beta of 0.85.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on NKTX shares. Mizuho dropped their target price on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research report on Thursday, November 21st. RODMAN&RENSHAW upgraded shares of Nkarta to a “strong-buy” rating in a research note on Wednesday, October 9th. Needham & Company LLC decreased their price target on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Rodman & Renshaw began coverage on shares of Nkarta in a research note on Wednesday, October 9th. They set a “buy” rating and a $14.00 price target on the stock. Finally, HC Wainwright decreased their price target on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Monday, November 11th. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Nkarta has an average rating of “Buy” and an average target price of $15.00.

Institutional Investors Weigh In On Nkarta

Several institutional investors and hedge funds have recently made changes to their positions in NKTX. Erste Asset Management GmbH acquired a new stake in shares of Nkarta in the 3rd quarter valued at $33,000. GAMMA Investing LLC lifted its position in Nkarta by 110.9% during the 3rd quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock worth $45,000 after buying an additional 5,243 shares in the last quarter. Forefront Analytics LLC acquired a new position in Nkarta during the 2nd quarter worth about $70,000. Intech Investment Management LLC acquired a new position in Nkarta during the 3rd quarter worth about $74,000. Finally, SG Americas Securities LLC acquired a new position in Nkarta during the 3rd quarter worth about $93,000. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.